Metformin Treatment Ameliorates Liver Injury Indicating Fatty Liver Polycystic Ovary Syndrome

Background: Polycystic ovary syndrome (PCOS) is associated with obesity and insulin resistance (IR), two key features of the metabolic syndrome. Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of the metabolic syndrome, with its progressive form, non-alcoholic steatohepatitis (NASH), comprising a major health risk for affected patients. Metformin (MF) as insulin sensitizing agent leads to a decrease of hepatic IR and could thus possibly ameliorate NASH. The caspase 3-cleaved fragment of cytokeratin 18 (CK18), termed M30, has been established as a serum marker for NASH. This study was conduct…